Group 1 - Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. successfully held its IPO ceremony on September 25 [2] - The company, founded in 2010 and headquartered in Shanghai, is a national medical device distributor and part of the C&D Group [3] - The company engages in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals, maintaining long-term partnerships with over 100 well-known domestic and international high-value medical device manufacturers [3] Group 2 - Chairman Yu Feng emphasized that the company will leverage its listing as an opportunity to utilize capital market resources, focusing on industry pain points and enhancing hospital scenarios [9] - The company aims to embrace the intelligent era and actively serve the public and society, with a commitment to delivering better operational performance to shareholders and contributing to society [9]

Group 1: New Stock Performance - The recent performance of new stocks on the Beijing Stock Exchange remains highly active, with the stock of Sanxie Electric rising by over 860% on its first day of trading, closing up 785.62%, marking the highest first-day increase of the year [1] - Aifenda also saw a first-day increase of 170.03%, with a single subscription yield exceeding 16,000 yuan [1] Group 2: Upcoming IPOs - This week, there are five new stocks available for subscription, including three from the Growth Enterprise Market, one from the Shenzhen Main Board, and one from the Beijing Stock Exchange [3] - The first stock available for subscription on September 15 is United Power, a leader in the new energy vehicle power system industry, collaborating with major automotive brands [1][5] Group 3: Financial Projections - United Power expects to achieve a net profit of 750 million to 900 million yuan in the first three quarters of 2025, representing a year-on-year growth of 31.05% to 57.26% [5] - The projected revenue for United Power in the same period is between 1.4 billion and 1.55 billion yuan, indicating a growth of 30.62% to 44.61% compared to the previous year [6] Group 4: Other Companies' Projections - Jianfa Zhixin anticipates a net profit of 200 million to 222 million yuan for the first three quarters of 2025, reflecting a growth of 30% to 40% [7] - Jin Hua New Materials expects a decline in revenue to 1.063 billion yuan for the full year 2025, down 14.25%, with a net profit of 199 million yuan, a decrease of 5.47% [9] - Rui Li Ke Mi forecasts a net profit of 196 million to 220 million yuan for the first three quarters of 2025, with a growth rate of 11.96% to 25.67% [10][11] - Yunhan Xincheng projects a net profit of 77 million to 80 million yuan for the first three quarters of 2025, with a growth of 38.71% to 44.11% [12][13]

Group 1 - The listing ceremony for Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. is scheduled for September 25, 2025, from 08:55 to 09:30, and will be live-streamed by Quanjing Roadshow [1][3] - Shanghai C&D INNOSTIC, established in 2010 and headquartered in Shanghai, is a member of the C&D Group and operates as a national medical device distributor [3] - The company engages in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals, maintaining long-term partnerships with over 100 well-known domestic and international high-value medical device manufacturers [3] Group 2 - The agenda for the listing ceremony includes watching a promotional video, speeches from leaders, ringing the opening bell, and a group photo session [3]

Core Viewpoint - Jianfa Zhixin (建发致新) is set to launch its initial public offering (IPO) on the ChiNext board, aiming to enhance its market presence and operational capabilities in the medical device supply chain sector [1][3]. Company Overview - Founded in 2010 and headquartered in Shanghai, Jianfa Zhixin focuses on the medical device supply chain, operating in a rapidly growing industry driven by aging population, policy support, and technological innovation [3]. - The company has established itself as a key player in the medical device sector, providing services to over 3,300 hospitals across 31 provinces and regions in China, with a projected revenue of 17.9 billion in 2024 and a compound annual growth rate (CAGR) exceeding 20% over the past five years [3][5]. Business Model and Services - Jianfa Zhixin primarily engages in direct sales and distribution of medical devices, offering centralized operation services for medical consumables (SPD) [5]. - The company plays a crucial role in the medical device supply chain, linking manufacturers, distributors, and healthcare institutions [5]. Financial Performance - The company has demonstrated strong growth in its main business, with revenue growth rates of 18.57%, 29.89%, and 16.01% for the years 2022, 2023, and 2024, respectively [8]. - Jianfa Zhixin plans to expand its product lines and brand partnerships to enhance service coverage to healthcare institutions, capitalizing on the growing market and increasing concentration in the medical device sector [8]. IPO Objectives - The funds raised from the IPO will be used to improve the precision and intelligence of its information systems for medical device distribution, optimize financial structure, and reduce operational risks [5]. - The IPO is expected to enhance the company's visibility and competitiveness in the market, positioning it as a leading medical device distribution service provider in China [5].

Core Viewpoint - Jianfa Zhixin (301584) successfully held its initial public offering (IPO) online roadshow on September 15, 2023, and will begin subscription on September 16, 2023 [1] Group 1: Company Overview - Jianfa Zhixin was established in 2010 and is headquartered in Shanghai, being a member of Jianfa Group [1] - The company operates as a national medical device distributor, focusing on direct sales and distribution, and provides centralized operation services for medical consumables to end hospitals [1] - Jianfa Zhixin has established long-term stable partnerships with over 100 well-known domestic and international high-value medical device manufacturers [1] Group 2: Business Operations - As of the end of the reporting period, the company has collaborated with over 3,300 hospitals across 31 provinces, municipalities, and autonomous regions in China, including more than 1,600 tertiary hospitals [2] - Jianfa Zhixin is one of the leading companies in the medical device distribution sector, offering a wide range of products and efficiently responding to the needs of medical institutions [2] - The company provides multiple services in its direct sales business, including channel access, central warehousing, logistics distribution, hospital inventory management, settlement management, and receivables management [2] - Utilizing information management technology, Jianfa Zhixin has achieved organic coordination of warehouses nationwide, enabling flexible and rapid terminal distribution and bidirectional logistics capabilities [2] - This operational model meets the procurement needs of end hospitals for small batches, high frequency, and diverse specifications of high-value medical devices, ensuring the safety, stability, and timeliness of product supply for surgical procedures [2]

Core Viewpoint - Jianfa Zhixin (301584) successfully held its online roadshow for its initial public offering (IPO) on the ChiNext board, with subscription starting on September 16 [1] Group 1: Company Overview - Jianfa Zhixin was founded in 2010 and is headquartered in Shanghai, being a member of Jianfa Group [1] - The company operates as a national medical device distributor, focusing on direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to hospitals [1] - Jianfa Zhixin has established long-term stable partnerships with over 100 well-known domestic and international high-value medical device manufacturers [1] Group 2: Business Model and Innovation - The company has developed a unique and innovative business model by addressing pain points in traditional medical device distribution and exploring the needs across the industry chain [2] - Jianfa Zhixin leverages modern technologies such as information management, IoT, and big data to enhance its management and service models, providing more modernized distribution services for the medical device industry [2] - The company's core competitiveness is built on innovations in technology, service, and management, reflecting its characteristics of innovation, creativity, and technical advancement [2]

Core Viewpoint - The document outlines the underwriting and sponsorship of Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd.'s initial public offering (IPO) on the ChiNext board by CITIC Securities, emphasizing the company's compliance with relevant laws and regulations, and its strong growth potential in the medical device industry [2][8]. Section 1: Basic Information of the Securities Issuance - The underwriting institution is CITIC Securities Co., Ltd. [4] - The issuer, Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd., was established on August 30, 2010, and transformed into a joint-stock company on November 8, 2017, with a registered capital of 358.095232 million RMB [3][4]. Section 2: Underwriting Institution's Commitment - CITIC Securities has conducted due diligence and confirmed that the issuer meets the legal requirements for the IPO, ensuring that the application documents are accurate and complete [7][8]. Section 3: Underwriting Institution's Opinions on the Securities Issuance - The underwriting institution believes that the issuer possesses the necessary conditions for the IPO, including a sound governance structure, strong operational performance, and a promising development outlook [8][10]. - The issuer's main business is the direct sales and distribution of medical devices, which aligns with national industrial policies and development strategies [10][12]. Section 4: Financial Performance - The company's revenue for the reporting periods was 1,188.2474 million RMB, 1,544.3269 million RMB, and 1,792.2751 million RMB, with year-on-year growth rates of 29.97% and 16.06% for 2023 and 2024, respectively [22]. - The net profit for the same periods was 189.2198 million RMB, 226.8766 million RMB, and 273.7902 million RMB, with increases of 19.90% and 20.68% for 2023 and 2024 [22]. Section 5: Industry Positioning - The issuer operates in the medical device distribution sector, which is classified under "F515 Medical and Medical Equipment Wholesale" according to national industry standards, and is compliant with the ChiNext board's industry requirements [18][21]. - The issuer's business model incorporates innovative technologies such as information management and IoT to enhance operational efficiency and reduce costs in the medical device supply chain [19][20]. Section 6: Risk Factors - The company faces risks associated with high asset-liability ratios and low liquidity ratios, which could impact its operational stability if financing conditions tighten [21][22]. - The issuer's reliance on major suppliers and potential changes in supplier relationships could adversely affect its business operations [26][30].